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Background: Cerium dioxide (CeO2) nanoparticles have potential therapeutic applications 
and are widely used for industrial purposes. However, the effects of these nanoparticles on pri-
mary human cells are largely unknown. The ability of nanoparticles to exacerbate pre-existing 
inflammatory disorders is not well documented for engineered nanoparticles, and is certainly 
lacking for CeO2 nanoparticles. We investigated the inflammation-modulating effects of CeO2 
nanoparticles at noncytotoxic concentrations in human peripheral blood monocytes.
Methods: CD14+ cells were isolated from peripheral blood samples of human volunteers. Cells 
were exposed to either 0.5 or 1 µg/mL of CeO2 nanoparticles over a period of 24 or 48 hours with or 
without lipopolysaccharide (10 ng/mL) prestimulation. Modulation of the inflammatory response 
was studied by measuring secreted tumor necrosis factor-alpha, interleukin-1beta,   macrophage 
chemotactic protein-1, interferon-gamma, and interferon gamma-induced protein 10.
Results: CeO2 nanoparticle suspensions were thoroughly characterized using dynamic light 
scattering analysis (194 nm hydrodynamic diameter), zeta potential analysis (−14 mV), and 
transmission electron microscopy (irregular-shaped particles). Transmission electron microscopy 
of CD14+ cells exposed to CeO2 nanoparticles revealed that these nanoparticles were efficiently 
internalized by monocytes and were found either in vesicles or free in the cytoplasm. However, 
no significant differences in secreted cytokine profiles were observed between CeO2 nanoparticle-
treated cells and control cells at noncytotoxic doses. No significant effects of CeO2 nanoparticle 
exposure subsequent to lipopolysaccharide priming was observed on cytokine secretion. 
Moreover, no significant difference in lipopolysaccharide-induced cytokine production was 
observed after exposure to CeO2 nanoparticles followed by lipopolysaccharide exposure.
Conclusion: CeO2 nanoparticles at noncytotoxic concentrations neither modulate pre-existing 
inflammation nor prime for subsequent exposure to lipopolysaccharides in human monocytes 
from healthy subjects.
Keywords: cerium dioxide, nanoparticle, nanomedicine, inflammation, human monocyte, 
lipopolysaccharides
Introduction
Nanomedicine is expected to benefit from cerium dioxide (CeO2) nanoparticle use 
in antioxidant therapy,1 neuroprotection,2 radioprotection,3 and ocular protection.4 
Apart from these nanomedicinal uses, various industrial applications of CeO2 nano-
particles include catalysis,5 ultraviolet absorbance,6,7 oxygen sensing,8 solar and fuel 
cells,9 and polishing (for glasses, lenses, television tubes, fuel cells, and precision 
optics).10 Moreover, CeO2 nanoparticles have significant environmental health sig-
nificance due to their widespread use as a diesel fuel additive. Indeed, it has been 
documented that addition of CeO2 to diesel decreases fuel consumption by 5%–8% and 
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  emission of   combustion-derived nanoparticles and unburned 
  hydrocarbons by up to 15%.11,12 However, the accompany-
ing release of CeO2   nanoparticles into the environment 
could exert   unexpected health effects.13 For this reason, the 
Organization for   Economic Cooperation and Development 
has included CeO2 nanoparticles in the priority list of 
  nanomaterials requiring urgent evaluation.14
Most human diseases are associated with local or systemic 
inflammatory responses. Moreover, exposure to environmen-
tal proinflammatory agents is ubiquitous; for example, we are 
all exposed to bacterial lipopolysaccharides, either through 
ingestion (contaminated food or water) or inhalation (house 
dust, particulate matter, diesel exhaust particles).   Furthermore, 
many epidemiological and experimental studies have shown 
that individuals with pre-existing inflammatory conditions are 
more prone to the adverse effects of environmental injury.15–17 
Indeed, aggravation of pre-existing inflammation has been 
documented after exposure to particulate air pollution and 
various types of nanoparticles.18–21
This study was designed to investigate the inflammation-
modulating effects of CeO2 nanoparticles in human peripheral 
blood monocytes at noncytotoxic exposure concentrations. 
The proposed uses of CeO2 nanoparticles in nanomedicine 
make peripheral blood monocytes important target cells at 
the portal of entry of nanoparticles into the human body. 
These cells are an essential link between the adaptive and 
innate immune responses because they develop into vari-
ous forms of antigen-presenting cells (macrophages, den-
dritic cells). We show here that noncytotoxic exposures to 
CeO2 nanoparticles do not prime or aggravate pre-existing 
lipopolysaccharide-induced inflammation.
Materials and methods
Study subjects and isolation of cells
This study was approved by the National Institute of 
  Environmental Health Sciences institutional review board. 
Adult human volunteers without any history of a chronic 
medical condition (hepatitis B, hepatitis C, or human immuno-
deficiency virus) and currently not taking any type of medica-
tion were recruited to the National Institute of Environmental 
Health Sciences Clinical Research Unit. The demographics 
of the study population are shown in Table 1. Recruited vol-
unteers underwent phlebotomy, and up to 300 mL of whole 
blood were withdrawn from an antecubital vein into citrated 
tubes. Mononuclear fraction was isolated using gradient 
centrifugation, and CD14+ cells were purified using magnetic 
beads according to the manufacturer’s recommendations 
(Miltenyi Biotec, Boston, MA). By this method, 95%–99% 
viable pure human monocytes were obtained, confirmed by 
flow cytometry and cytospin preparations.
Cells and culture conditions
After isolation, the cells were seeded in 24-well cell culture 
plates (400,000 cells per well) in x-vivo™ cell culture medium 
(Lonza, Walkersville, MD) supplemented with 1% human 
serum and antibiotics (1% solution of   penicillin 100 µg/mL 
and streptomycin 100 µg/mL; Invitrogen   Carlsbad, CA) and 
incubated at 37°C, 5% CO2, and 95% relative humidity for 
2 hours (to allow sufficient time for attachment of cells). 
After cell attachment, the cell culture medium was aspirated 
and the cells were washed thoroughly with fresh medium to 
remove unattached cells. The cells were then incubated in 
fresh prewarmed medium containing the desired doses of 
nanoparticles or lipopolysaccharides for the different time 
intervals (24 or 48 hours).
Nanoparticles
CeO2 nanoparticles were obtained from Meliorum   Technologies 
(Rochester, NY) and characterized in the Center for Envi-
ronmental Implications of Nanotechnology,   University of 
California. Studied characteristics included shape/diameter 
(transmission electron microscopy), crystal structure (X-ray 
diffraction analysis), surface area (Brunauer–Emmitt–Teller 
method), suspension behavior, hydrodynamic diameter, and 
size distribution (dynamic light scattering), zeta potential 
(ZetaSizer Nano; Malvern Instruments,   Westborough, MA), 
purity (thermogravimetric analysis), and bacterial endotoxins 
(limulus amebocyte lysate assay). Dynamic light scattering 
analysis of the CeO2 nanoparticle suspensions (at 1 µg/mL) 
in cell culture medium was done to determine the size 
  distribution. A nanoparticle stock solution (1 mg/mL) was pre-
pared in water and stored at 4°C in a refrigerator. All exposure 
suspensions were freshly prepared from this stock solution after 
sonication at three pulses of 20 seconds at 235 W each with 
a 5-second pause using a Mesonix S 4000 cup horn sonicator 
(Qsonica LLC, Newtown, CT). After sonication, the particles 
were suspended in cell culture medium and used to expose 
cells within 5 minutes after vortexing.
These are the best known commercially available CeO2 
nanoparticles which have been widely explored in various 
Table 1 Population demographics
Age  
(years)
Sex 
(male/female)
Race 
(African American/ 
Asian/Caucasian)
Medication
44 ± 12 21/16 8/2/27 None
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fields (toxicology, biology, nanotechnology) and have an 
excellent publication record. From an environmental perspec-
tive, study of these particles is very valid because the par-
ticles and their aggregates lie within the range of respirable 
particles (less than 3 µm) which can deposit in the alveolar 
regions of the lungs.
Experimental design
A low effective dose of lipopolysaccharides (Escherichia coli 
O111:B4, 10 ng/mL) was used to induce an inflammatory 
response in the cells. The total duration of the experiments 
was fixed to either 24 or 48 hours and the ability of the 
nanoparticles to modulate pre-existing inflammation or to 
prime for subsequent inflammation was assessed. A graphical 
description of the protocols is given in Figure 1. To assess the 
ability of the nanoparticles to modulate pre-existing inflam-
mation, the cells were incubated with lipopolysaccharides for 
16 hours and then exposed to CeO2 nanoparticles for 8 hours 
(24-hour protocol) or 32 hours (48-hour protocol). On the 
other hand, to assess the ability of the nanoparticles to prime 
for subsequent exposure to inflammatory agents, the cells 
were exposed to CeO2 nanoparticles for 16 hours and then 
exposed to lipopolysaccharides for 8 hours or 32 hours (for 
the 24-hour and 48-hour protocols, respectively).
Transmission electron microscopy  
for nanoparticle-cell interaction
Cells were grown in two-chamber cell culture slides and 
treated with 0.5 or 1 µg/mL CeO2 nanoparticles for 24 hours. 
The cells were fixed in 3% glutaraldehyde and processed for 
transmission electron microscopic analysis. Thin sections 
(60–90 nm) were cut and placed on Formvar copper grids 
then stained with uranyl acetate and lead citrate. After stain-
ing, sections were examined on a FEI Tecnai 110 kV micro-
scope at 80 kV and digital photomicrographs were taken.
Toxicity analysis
A propidium iodide incorporation assay was performed to 
evaluate membrane integrity and cytotoxicity. Briefly, cells 
were trypsinated after 24-hour or 48-hour exposures using 
trypsin-EDTA. The action of trypsin was inhibited using 10% 
fetal bovine serum, and the cells were centrifuged at 960 rpm 
for 6 minutes. Cells were resuspended in 500 µL of warm cell 
culture medium containing 2.5 µg/mL of propidium iodide. 
Analysis was performed on a FACSAria II (BD Biosciences, 
Franklin Lakes, NJ) instrument at 488 nm excitation and 
610 nm emission wavelengths. After elimination of cellular 
debris, at least 10,000 cells were analyzed to determine the 
percentage of propidium iodide-positive cells.
Measurement of cytokines
At the end of the desired incubation time, the supernatants 
were recovered, centrifuged at 10,000 g for 15 minutes at 4°C, 
and stored at −80°C till further analysis. The concentration 
of tumor necrosis factor alpha (TNF-α) was evaluated using 
a commercially available human enzyme-linked immunosor-
bent assay kit (R&D Systems, Minneapolis, MN) according to 
the manufacturer’s recommendations. The concentrations of 
interleukin-1beta (IL-1β), macrophage chemotactic protein-1, 
IP-10, and interferon-gamma (INF-γ) were determined using 
the BD Bioplex assay system (BD Biosciences).
Statistical analysis
Data are presented as the mean ± standard error of the 
mean and were analyzed by analysis of variance, followed 
by Tukey’s test using GraphPad (GraphPad Prism 4.01, 
  GraphPad Software Inc, San Diego, CA).   A level of P , 0.05 
(two-tailed) was considered to be statistically significant.
Results
Nanoparticle characteristics
The nanoparticle characteristics are presented in Table 2 
and Figure 2. Transmission electron microscopic analysis 
revealed that the CeO2 nanoparticles were irregular in shape 
and tended to aggregate (Figure 2A). The X-ray diffraction 
analysis pattern is shown in Figure 2B, demonstrating that 
the particles are highly crystalline and all peaks could be 
indexed to cubic fluorite CeO2. Dynamic light scattering 
analysis revealed that the CeO2 nanoparticles (1 µg/mL) 
8 or 32 hours 8 or 16 hours
Inflammation
16 or 32 hours 16 hours LPS
CeO2
CeO2
LPS
LPS priming Ceria priming
Human peripheral
blood monocytes
Figure 1 Schematic presentation of the experimental design used in the present 
study to elaborate the inflammation-modulating effects of CeO2 nanoparticles.
Abbreviation: LPS, lipopolysaccharides.
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suspended as a single (96 nm size) population in x-vivo cell 
culture media supplemented with 1% heat inactivated human 
serum. Further, these particles had −13 mV zeta potentials 
in the same suspension.
CeO2 nanoparticles are internalized  
by human monocytes
Transmission electron microscopic analysis of nanoparticle-
cell interactions indicated that the CeO2 nanoparticles were 
taken up by human monocytes either in vesicles/phagosomes 
(mixed with the other debris) or were free in the cytoplasm 
(Figure 3).
CeO2 nanoparticles induce cytotoxicity
The cytotoxic potential of CeO2 nanoparticles was tested 
using propidium iodide staining (Figure 4). Figure 4A shows 
the cytotoxic response after exposure to different doses 
of CeO2 nanoparticles. We demonstrated that CeO2 nano-
particles induce a cytotoxic response at doses .1 µg/mL 
(Figure 4A). We therefore decided to use only the lower doses 
(#1 µg/mL) for our inflammatory response experiments. We 
confirmed that addition of 10 ng/mL lipopolysaccharides to 
these doses of CeO2 did not alter cytotoxicity (Figure 4B).
CeO2 nanoparticles do not modulate 
inflammatory response  
to lipopolysaccharides
The ability of CeO2 nanoparticles to modulate or prime the 
inflammatory response to lipopolysaccharides was assessed 
using the protocol described in Figure 1. As presented in 
Figure 5, we did not find any significant difference in the 
production of TNF-α, a proinflammatory cytokine, after CeO2 
nanoparticle exposure. A similar pattern was observed for 
IL-1β production (Figure 6). IFN-γ and IP-10 also showed 
a similar trend, and the results are presented in Table 3. 
Macrophage chemotactic protein-1 production was increased 
by lipopolysaccharide exposure only at 24 hours and this 
increase was no longer detected at 48 hours.
Discussion
Nanotechnology has shown promising potential to improve 
the quality of everyday life and has led to the production 
of a variety of novel materials for industrial, consumer 
product, and medicinal applications. However, there is a 
lack of adequate data about the effects of these nanomate-
rials on human health and the environment. In particular, 
the effects of these novel materials on susceptible popula-
tions (with pre-existing health issues) are rarely addressed. 
Evaluation of such effects becomes even more pertinent 
when considering the proposed use of nanomaterials in the 
medical sector. This experimentation aimed at: elucidating 
the inflammatory potential of CeO2 nanoparticles; evaluat-
ing the possibility of aggravation of a pre-existing inflam-
matory response after exposure to CeO2 nanoparticles; and 
exploration of the ability of CeO2 nanoparticles to prime for 
subsequent exposure to an inflammatory agent. Our results 
indicate that CeO2 nanoparticles do not significantly change 
the lipopolysaccharide-induced inflammatory responses of 
peripheral blood monocytes at noncytotoxic doses. Moreover, 
CeO2 nanoparticles did not prime human monocytes for 
subsequent exposure to lipopolysaccharides.
Controversy exists in the published literature about 
the inflammatory effects of CeO2 nanoparticles. Hirst 
et al reported anti-inflammatory effects by demonstrat-
ing reduction of inducible nitric oxide expression in 
J774A.1   macrophages22 and Niu et al reported suppression of 
inflammatory mediators (macrophage chemotactic protein-1, 
IL-6, and TNF-α) production by CeO2 nanoparticles in a 
murine cardiomyopathy model.23 Moreover, CeO2 nanopar-
ticles have been reported to reduce oxidative signaling and 
cell death induced by cigarette smoke, diesel exhaust, and 
hydrogen peroxide.24–26 In contrast, other in vitro and in vivo 
experiments suggest that CeO2 nanoparticles produce inflam-
mation, reactive oxygen species, lipid peroxidation, liver and 
lung damage, acute and chronic fibrotic effects, and altered 
macrophage phenotypes.27–31 Variation in target species/
cell type, experimental design (exposure concentration and 
duration) and nanoparticle characteristics (shape, size, purity, 
Table 2 Particle characteristics
Physicochemical  
properties
Characterization  
techniques
Unit CeO2
Primary size TEM/SEM 
XRD
nm 
nm
10–30 
7
Particle size
  Ex-vivo medium 
  Water
Malvern zeta-sizer nm 96 
231
Phase and structure XRD 100% ceria  
cubic
Morphology TEM Irregular
Surface area BET m2 g−1 93.8
pHiep (isoelectric point) ZetaPALS 7.8
Zeta potential 
  Ex-vivo medium 
  Water
 
ZetaPALS
 
mV
 
−13 
19.1
Purity TGA* Wt% 95.41
Moisture content TGA Wt% 4.01
Acid content TGA Wt% 0.85
Note: *Thermogravimetric analysis.
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Figure 2 Physicochemical characterization of CeO2 nanoparticles. (A) Transmission electron microscopic images of nanoparticle suspensions (low and high magnification). 
(B) X-ray diffraction analysis pattern of CeO2 nanoparticles. (C) Dynamic light scattering analysis of CeO2 nanoparticles suspension (1 µg/mL) in ex-vivo cell culture medium 
performed using Malvern Zetasizer Nano.
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A
B
C
Figure 3 Transmission electron microscopic analysis of CeO2 nanoparticle-treated human monocytes. Cells were treated with (A) media, (B) 0.5 µg/mL, and (C) 1 µg/mL 
CeO2 nanoparticles for 24 hours and ultrastructural changes were observed.
Note: Arrows point to the particle aggregates.
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Figure 4 Evaluation of human monocyte cytotoxicity after exposure to CeO2 nanoparticles. (A) Cells were treated with different doses of nanoparticles (0.5–10 µg/mL) 
for 24 or 48 hours, stained with propidium iodide for membrane integrity, and analyzed using flow cytometry. (B) Cells were exposed to noncytotoxic doses of CeO2 
nanoparticles either in the presence or absence of lipopolysaccharides for 24 or 48 hours as shown in Figure 1, stained with propidium iodide and analyzed using flow 
cytometry.
Notes: Data are presented as the mean ± standard error of the mean and analyzed by analysis of variance, followed by Tukey’s post hoc test. n = 5; *P , 0.05; **P , 0.01; 
***P , 0.001.
Abbreviations: PI, propidium iodide; LPS, lipopolysaccharides.
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Figure 5 Evaluation of inflammation modulating ability of CeO2 nanoparticles in human monocytes. Cells were treated according to the protocol presented in Figure 1 and 
the amount of TNF-α in cell culture supernatants was analyzed by enzyme-linked immunosorbent assay according to the manufacturer’s recommendations.
Notes: Data are presented as the mean ± standard error of the mean and analyzed by analysis of variance, followed by Tukey’s post hoc test. n = 5–10; ***P , 0.001.
Abbreviations: LPS, lipopolysaccharides; TNF-α, tumor necrosis factor-alpha.
agglomeration, and surface modifications) could be possible 
reasons for these differences and make cross-study compari-
sons difficult. Further, CeO2 nanoparticles can be prepared by 
different methods that lead to differences in relative propor-
tions of Ce3+/Ce4+ ions (one of the reasons proposed for CeO2 
nanoparticle-induced reactive oxygen species scavenging).32 
Nevertheless, we did not observe any significant differences 
in cytokine release of human immune cells after exposure to 
noncytotoxic doses of CeO2 nanoparticles.
The present study is unique in the sense that it addresses 
the question of pre-existing inflammatory conditions in human 
cells which are likely to exist in the event of therapeutic 
application of CeO2 nanoparticles. Indeed, it has already been 
suggested that during the development of therapeutic nano-
materials, their biocompatibility should also be evaluated in 
the presence of other agonists such as   lipopolysaccharides.33 
Moreover, studies in mice and in cell lines may not accurately 
predict nanoparticle-elicited responses in primary human 
cells. Lastly, CeO2 nanoparticle-induced protective effects 
have been reported in oxidative stress-dependent processes, 
but no attempt has been made to explore the possibility of 
similar effects on oxidative stress-independent mechanisms 
(such as lipopolysaccharide-induced inflammatory responses). 
Our study addresses these gaps in our knowledge. Our data 
suggest that pre-existing inflammation does not seem to 
alter the response to CeO2 nanoparticles significantly. On 
the other hand, we did not find any beneficial effect of CeO2 
nanoparticles on lipopolysaccharide-induced cytokine release, 
suggesting that the previously reported antioxidant effects of 
CeO2 nanoparticles in macrophages may be limited in their 
scope of action, and do not extend to a general   downregulation 
of the inflammatory response.
We did find CeO2 nanoparticle internalization by human 
monocytes, either in the form of vesicles or free in cytoplasm. 
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Figure 6 Evaluation of inflammation-modulating ability of CeO2 nanoparticles in human monocytes. Cells were treated according to the protocol presented in Figure 1 and 
the amount of IL-1β in cell culture supernatants was analyzed by the Bioplex assay according to the manufacturer’s recommendations.
Notes: Data are presented as the mean ± standard error of the mean and analyzed by analysis of variance, followed by Tukey’s post hoc test. n = 5–10; ***P , 0.001.
Abbreviations: IL-1β, tumor necrosis factor-alpha; LPS, lipopolysaccharides.
Table 3A Cytokine concentrations without priming
INF-γ IP-10 MCP-1
24 h 48 h 24 h 48 h 24 h 48 h
Control 18.4 ± 1.7 17.6 ± 1.7 129.8 ± 24.06 28.79 ± 6.33 875.8 ± 167.2 3511 ± 870.8
CeO2 0.5 µg/mL 17.7 ± 1.5 20.5 ± 2.3 106.8 ± 22.7 38.25 ± 10.7 815.6 ± 116.0 4219 ± 929.4
CeO2 1 µg/mL    18 ± 1.5 17.0 ± 2.0 139.1 ± 29.2   46.0 ± 9.5  1336 ± 573.9 4287 ± 912
Abbreviations: INF-γ, interferon-gamma; IP-10, interferon gamma-induced protein 10; MCP-1, macrophage chemotactic protein-1.
These results are in agreement with previous studies reporting 
endocytosis of CeO2 nanoparticles into cells.34,35 These results 
indicate that CeO2 nanoparticles have good biocompatibility 
at the tested concentrations and their presence inside the cells 
did not influence the production of the cytokines studied.
We and others have previously shown that nanoparticles 
can adsorb cytokines and other biologically significant pro-
teins (for example, enzymes) onto their surfaces and thus 
may interfere with accurate assessment of their inflammatory 
potential.36–38 We checked the possibility of TNF-α binding 
by incubating the nanoparticles with a known concentration 
of TNF-α for 24 or 48 hours and reanalyzing the concentra-
tions of cytokines by enzyme-linked immunosorbent assay. 
We did not find any difference between untreated and nano-
particle-treated samples, indicating that CeO2 nanoparticles 
did not adsorb cytokines.
Our study does have certain limitations. These include use 
of lipopolysaccharide priming (which can skew the inflam-
matory responses towards Th1) and use of Th1 cytokines 
only to assess inflammation. However, this does not limit 
the scope of our study because lipopolysaccharide expo-
sure is well described and one of the best environmentally 
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  relevant models available in which to conduct inflammation 
  modulation studies. More in vivo studies are in progress to 
study Th1/Th2 polarization of responses and to elaborate the 
possibilities of modulation of allergic lung inflammation after 
exposure to CeO2 nanoparticles.
Conclusion
Overall, our results suggest that, under noncytotoxic 
exposure conditions, CeO2 nanoparticles neither modulate 
nor prime for a lipopolysaccharide-induced inflammatory 
response in human peripheral blood monocytes. Our results 
emphasize the need to evaluate the effects of nanomaterials 
in the presence of agonists (such as lipopolysaccharides) 
which are expected to occur in real-life conditions. In the 
future, further studies on primary human cells focusing 
on susceptible populations (with pre-existing diseases) 
are warranted for identification of the realistic hazards of 
nanomaterials.
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